Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 8, Issue 5, 2012, Pages 313-317

  Shakir, Faiz A ^a   Ali, Tauseef ^a   Bigham, Aletha C ^b   Ballard, Jimmy D ^a   Miner, Philip B ^b   Philpott, Jessica R ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Oklahoma Foundation for Digestive Research   (United States)

Author keywords

Antibodies; Clostridium difficile; Inflammatory bowel disease; Serum

Indexed keywords

ANTIBODY; CLOSTRIDIUM DIFFICILE TOXIN B; IMMUNOGLOBULIN G ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; HIGH RISK POPULATION; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; RELAPSE; REMISSION; ULCERATIVE COLITIS;

EID: 84862495448     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397. (Pubitemid 30084537)
2. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162:678-684. (Pubitemid 20266159)
3. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344. (Pubitemid 46401530)
4. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205-210. (Pubitemid 351158048)
5. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162-1169.
6. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253-264.
7. Sinh P, Barrett TA, Yun L. Clostridium difficile infection and inflammatory bowel disease: a review. Gastroenterol Res Pract. 2011;2011:136064.
8. Sánchez-Hurtado K, Corretge M, Mutlu E, McIlhagger R, Starr JM, Poxton IR. Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. J Med Microbiol. 2008;57(pt 6):717-724. (Pubitemid 351842063)
9. Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010;28:965-969.
10. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med. 1995;181:453-461.
11. Nguyen ML, Terzyan S, Ballard JD, James JA, Farris AD. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect Immun. 2009;77:4714-4723.
12. Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2011 Nov 8. Epub ahead of print.
13. Fararjeh M, Mohammad MK, Bustanji Y, Alkhatib H, Abdalla S. Evaluation of immunosuppression induced by metronidazole in Balb/c mice and human peripheral blood lymphocytes. Int Immunopharmacol. 2008;8:341-350.